Medicure Inc. is gearing up to release its earnings on May 20, 2026, following a year marked by significant challenges and strategic shifts. With no EPS estimates available, investors are keen to see how the company navigates its financial hurdles.
Medicure Inc. (MPH.V) will report its earnings after the market closes on May 20, 2026, for the fiscal period ending March 31, 2026. While the company has not provided EPS estimates, its recent performance and market cap of CA$12.42 million suggest that stakeholders will be closely monitoring the results for signs of recovery or continued struggles.
Investor takeaway: Long-term investors should focus on the strategic moves Medicure is making, especially in light of its recent acquisition and leadership changes.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Medicure Inc
MPH.V
MPH.V
Medicure Inc
WealthAwesomeMarket cap
$11.17M
52W high
$1.43
52W low
$0.85
1W change
+0.94%
Beta
1.04
Analyst Price Targets
Based on analyst covering MPH
Wall Street analysts forecast MPH stock price to rise 161.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.80
+161.7% Upside
Current Price
C$1.07
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MPH's historical volatility
30-Day Vol
160.7%
Annualized
90-Day Vol
150.9%
Annualized
Trend (90d)
-41.1%
Annualized drift
90d Mean
C$0.92
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.02 | C$0.59 โ C$1.77 |
| 60 trading days | C$0.97 | C$0.44 โ C$2.13 |
| 90 trading days | C$0.92 | C$0.35 โ C$2.41 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Why EPS Estimates Matter for Medicure's Upcoming Report
The lack of EPS estimates for Medicure's upcoming earnings report highlights uncertainty in its financial outlook. Investors will be looking for any signs of improvement in the company's profit margins and overall revenue, especially after reporting a net loss last year.
Bull case
Potential for Recovery: - Medicure's recent acquisition of Gateway Medical Pharmacy could enhance its revenue streams. - The company is actively engaging in clinical trials, which may lead to future product launches. - A forward P/E of 13.48x suggests that if profitability improves, the stock could be undervalued compared to peers.
Bear case
Ongoing Challenges: - Medicure reported a significant net loss of CA$7.1 million for 2025, raising concerns about its financial stability. - The resignation of its President and COO could lead to operational disruptions. - With a profit margin of -24.60%, the company faces substantial hurdles to profitability.
Understanding Medicure's Recent Strategic Moves
Medicure has been active in expanding its business, particularly through the acquisition of Gateway Medical Pharmacy. This move is aimed at bolstering its direct-to-consumer pharmacy business, which could provide a much-needed revenue boost. Additionally, the company is involved in clinical trials that could pave the way for new product offerings, potentially improving its financial outlook.
The Impact of Leadership Changes on Medicure
The resignation of Dr. Neil Owens as President and COO raises questions about the company's leadership stability. With Dr. Albert D. Friesen stepping in, investors will be watching closely to see how this transition affects Medicure's strategic direction and operational efficiency, especially as it prepares for its earnings report.
Financial Metrics to Watch in Medicure's Earnings
With a market cap of CA$12.42 million and a forward P/E of 13.48x, Medicure's financial metrics indicate a company at a crossroads. Investors should pay attention to any updates on profit margins and revenue growth, especially given the reported net loss last year. These figures will be crucial in assessing the company's path forward.
Advertisement
